Literature DB >> 24876590

Changes in Insulin Requirements From the Onset of Continuous Subcutaneous Insulin Infusion (CSII) Until Optimization of Glycemic Control.

Ana Chico1, Diana Tundidor2, Lluis Jordana2, Ignasi Saigi2, Miguel A Maria2, Rosa Corcoy3, A de Leiva3.   

Abstract

The aim was to evaluate changes in insulin requirements from onset of continuous subcutaneous insulin infusion (CSII) until glucose optimization in type 1 diabetes and to determine patient characteristics to be considered when CSII is implemented. We retrospectively analyzed 74 type 1 diabetic patients over a follow-up of 5 months after starting CSII. Patients without a decrease in HbA1c levels at the end of follow-up were excluded. We compared total daily doses (TDD), basal/bolus distribution, basal diurnal/nocturnal proportion, number of basal segments, and HbA1c levels in relation to sex, age, body mass index (BMI), diabetes duration, and indication for CSII. At follow-up, HbA1c decreased by 0.75%, TDD decreased by 18%, basal rate was 60% of TDD, and diurnal basal rate was 60% of total basal rate. Insulin requirements were higher in males and in obese patients. Female patients and patients with longer diabetes duration showed a higher percentage of basal insulin. The number of basal segments was 4.9 ± 2.9. Basal requirements were higher in the second half of the nocturnal period. The dawn phenomenon was more relevant in men. Improvements in glycemic control were more marked in younger patients, in patients with higher HbA1c, in patients using more basal segments, and in patients initiating CSII for glucose control before pregnancy. Sex, diabetes duration, and BMI should be considered when initiating CSII. Our findings may help clinicians in clinical decision making regarding CSII therapy.
© 2014 Diabetes Technology Society.

Entities:  

Keywords:  glycated hemoglobin; insulin pump; type 1 diabetes

Year:  2014        PMID: 24876590      PMCID: PMC4455399          DOI: 10.1177/1932296813520205

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  18 in total

1.  Insulin requirement profiles of patients with type 2 diabetes after achieving stabilized glycemic control with short-term continuous subcutaneous insulin infusion.

Authors:  Yun-Hee Noh; Won-Jin Lee; Kyoung-Ah Kim; Inja Lim; Jun-Ho Lee; Ju-Han Lee; Seonguk Kim; Soo-Bong Choi
Journal:  Diabetes Technol Ther       Date:  2010-04       Impact factor: 6.118

2.  Characteristics of basal insulin requirements by age and gender in Type-1 diabetes patients using insulin pump therapy.

Authors:  Gary Scheiner; Bret A Boyer
Journal:  Diabetes Res Clin Pract       Date:  2004-12-22       Impact factor: 5.602

Review 3.  Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with diabetes.

Authors:  Bruce W Bode; William V Tamborlane; Paul C Davidson
Journal:  Postgrad Med       Date:  2002-05       Impact factor: 3.840

4.  Classification of distinct baseline insulin infusion patterns in children and adolescents with type 1 diabetes on continuous subcutaneous insulin infusion therapy.

Authors:  Paul-Martin Holterhus; Rainer Odendahl; Sandra Oesingmann; Rudolf Lepler; Verena Wagner; Olaf Hiort; Reinhard Holl
Journal:  Diabetes Care       Date:  2007-03       Impact factor: 19.112

5.  Basal rates and circadian profiles in continuous subcutaneous insulin infusion (CSII) differ for preschool children, prepubertal children, adolescents and young adults.

Authors:  Rainer Bachran; Peter Beyer; Christof Klinkert; Bettina Heidtmann; Joachim Rosenbauer; Reinhard W Holl
Journal:  Pediatr Diabetes       Date:  2011-05-05       Impact factor: 4.866

6.  Basal insulin requirements on continuous subcutaneous insulin infusion during the first 12 months after diagnosis of type 1 diabetes mellitus.

Authors:  Neesha Ramchandani; Mary Kristine Ellis; Shobhit Jain; Sonal Bhandari; Henry Anhalt; Noel K Maclaren; Svetlana Ten
Journal:  J Diabetes Sci Technol       Date:  2010-05-01

7.  Difference in insulin usage patterns with pubertal development in children with type 1 diabetes during transition from multiple daily injections to continuous subcutaneous insulin infusion (CSII) and through the CSII treatment.

Authors:  B Shashaj; N Sulli
Journal:  Diabetes Technol Ther       Date:  2009-12       Impact factor: 6.118

Review 8.  Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis.

Authors:  K Jeitler; K Horvath; A Berghold; T W Gratzer; K Neeser; T R Pieber; A Siebenhofer
Journal:  Diabetologia       Date:  2008-03-20       Impact factor: 10.122

Review 9.  Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes.

Authors:  John C Pickup; Eric Renard
Journal:  Diabetes Care       Date:  2008-02       Impact factor: 19.112

10.  Basal and bolus insulin requirements in children, adolescents, and young adults with type 1 diabetes mellitus on continuous subcutaneous insulin infusion (CSII): effects of age and puberty.

Authors:  Ayse Pinar Cemeroglu; Jason P Thomas; Luke T Vande Zande; Nga T Nguyen; Michael A Wood; Lora Kleis; Alan T Davis
Journal:  Endocr Pract       Date:  2013 Sep-Oct       Impact factor: 3.443

View more
  3 in total

Review 1.  Boluses in Insulin Therapy.

Authors:  Ralph Ziegler; Guido Freckmann; Lutz Heinemann
Journal:  J Diabetes Sci Technol       Date:  2016-07-10

2.  Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump.

Authors:  Mauro Boronat; Rosa M Sánchez-Hernández; Julia Rodríguez-Cordero; Angelines Jiménez-Ortega; Francisco J Nóvoa
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2015-01-01

3.  Determining starting basal rates of insulin infusion for insulin pump users: a comparison between methods.

Authors:  Nelson Chow; Daniel Shearer; Hamish G Tildesley; Jessica Aydin Plaa; Betty Pottinger; Monika Pawlowska; Adam White; Anne Priestman; Stuart A Ross; Hugh D Tildesley
Journal:  BMJ Open Diabetes Res Care       Date:  2016-03-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.